Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). Previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.